Exchange: NASDAQ·Updated 07:30 PM EST
QTTB logo

QTTB Q32 Bio Inc.

$8.29
$0.42
(4.82%)
Today
Closed $8.29
$0.00
(0.00%)
After Hours
Reported EarningsNov 4
Mkt Cap$260.64M
Vol344,086.00

About QTTB

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David S. Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.
57

Bullish Sentiment

How do you feel about QTTB?

focafoca99
$QTTB highlighted strong Q3 2026 results and durable Phase 2 data for bempikibart, plus new CMO and CDO hires.
3
Rayvio_News_Filter
$QTTB 🏥 Q32 Bio reported additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA trial of bempikibart, supporting further development as a chronic treatment for alopecia areata.
2
focafoca99
$QTTB joined the 2026 Jefferies Global Healthcare Conference in London for a fireside chat.
1

Advertisement|Remove ads.